Abstract: This invention concerns the treatment of cartilage disorder and osteoarthritis in particular. More specifically, it relates to the use of FGF-18 in treatment regimens of patients having a cartilage disorder such as osteoarthritis, such as for example knee osteoarthritis or secondary hip osteoarthritis. Specifically provided is a preferred treatment scheme comprising once weekly administration of an FGF-18 compound per treatment cycle.

Abstract: The present invention provides a method for treating a patient having demyelinating optic neuritis (DON) comprising the sequential or simultaneous administration of a steroid compound and an interferon-beta protein. It is found that early, aggressive treatment of IFN-b is beneficial in such a treatment regimen, for example where the interferon-beta protein is administered at a cumulative weekly dose of more than 12 MIL). The method according to the invention is particularly suitable and beneficial for treatment of patients having early stage DON. In particular, the DON that will benefit from being treated according to the present invention may be in subclinical stage.

Abstract: An injection device for injecting medication to a patient, comprising a surface (5) having a through hole (3) for passage of a needle, is characterised by further comprising a capacitive proximity sensor (12, 13, 30) for detecting proximity or contact of human skin to/with said surface (5).

Abstract: The invention relates to a device (1) for overturning containers (2), particularly roller bottles intended for cell cultures, characterized in that it comprises a rotation actuator (3) associated by means of a transmission shaft (13) to a reducer (4) and a dynamic brake (5), a support (17) and rods (7) gripping the container (2), said support (17) being joined to the rotation actuator (3) by means of a shifter (16) of the transmission shaft (13) of the mentioned rotation actuator (3), the rotation actuator (3) being actuated by means of a pneumatic foot pedal (18), and the mentioned rotation actuator (3) in turn being associated to a timer (19) indicating the end of the overturning time of the container (2).

Abstract: This invention relates to a novel protein, termed INSP201, herein identified as a cell surface glycoprotein, and to the use of this protein and nucleic acid sequences from the encoding gene in the diagnosis, prevention and treatment of disease.

Abstract: The present invention is in the field of the manufacture of recombinant proteins. More specifically, it relates to the use of a serum-free culture medium comprising an antioxidant for the production of recombinant dimeric gonadotropins. The antioxidant may be selected from the group consisting of L-glutathione, 2-mercaptoethanol, L-methionine and a combination of ascorbic acid and of (+)-alpha-tocoplierol.

Abstract: An injection device for injecting medication to a patient, comprising a surface (5) having a through hole (3) for passage of a needle, is characterised by further comprising a capacitive proximity sensor (12, 13, 30) for detecting proximity or contact of human skin to/with said surface (5).

Abstract: This invention relates to methods for use in industrial production of proteins. Specifically, the present invention provides a method of recycling solid supports for cultivation of anchorage-dependent cells such as, e.g., microcarriers and Fibra-Cel® disks. Solid supports recycled by a method of the present invention allow obtaining a protein productivity level comparable to the productivity level obtained with non-recycled solid support. The method comprises the steps of rinsing with water, rinsing with a sodium hydroxide solution and second rinsing step with water.

Abstract: The present invention relates to a process for the production of interferon beta, and to an interferon beta composition having a unique glycosylation pattern.

Abstract: The use of an aromatase inhibitor (AI) in the preparation of a medicament for use in inducing ovulation in a female suffering from anovulatory infertility which comprises administering to said female a single dose of the at least one aromatase inhibitor. The use of an aromatase inhibitor (AI) for the preparation of a medicament comprising a single dose of at least one aromatase inhibitor (AI) for administration to an ovulating female suffering from unexplained infertility or other types of ovulatory infertility early in one or more menstrual cycles. Such a medicament may also be administered to an anovulatory female in combination with a plurality of daily doses of follicle stimulating hormone (FSH) whereby the dosage levels of FSH may be reduced. The use of AI in the preparation of a medicament for administration to a female who is a poor responder to FSH, which comprises a combination of a single dose of AI with a plurality of daily doses of FSH is also disclosed.

Abstract: A medication delivery device includes a housing, a door coupled to the housing and moveable between a closed position and an open position. The door permits insertion of a medication container, containing liquid medication, into the housing in the open position. A door opening mechanism is coupled to the door. A push member is axially moveable between a retracted position and a non-retracted position and located external to the medication container. The push member enters the medication container and pushes the liquid medication out of the medication container. A lock mechanism is coupled to the door opening mechanism and prevents opening of the door when the push member is in the non-retracted position inside the medication container, wherein the lock mechanism automatically unlocks the door opening mechanism when the push member is in the retracted position.

Abstract: A medication delivery device includes a housing, a door coupled to the housing and moveable between a closed position and an open position. The door permits insertion of a medication container, containing liquid medication, into the housing in the open position. A door opening mechanism is coupled to the door. A push member is axially moveable between a retracted position and a non-retracted position and located external to the medication container. The push member enters the medication container and pushes the liquid medication out of the medication container. A lock mechanism is coupled to the door opening mechanism and prevents opening of the door when the push member is in the non-retracted position inside the medication container, wherein the lock mechanism automatically unlocks the door opening mechanism when the push member is in the retracted position.

Abstract: The invention relates to a process for the purification of IL-18 binding protein (IL-18BP) from a fluid using aqueous two-phase partitioning.

Abstract: Provided are compositions of cladribine and cyclodextrin which are especially suited for the oral administration of cladribine.

Abstract: Provided are compositions of cladribine and cyclodextrin which are especially suited for the oral administration of cladribine.

Abstract: The present invention is related to pharmaceutical Poloxamer hydrogel formulations containing an interferon. In particular, the invention relates to sustained release hydrogel formulations of interferon-beta, method of preparation and use thereof.

Abstract: The invention provides mutants of IL-18 with lower affinity to IL-18BP than the wild type IL-18 molecule.

Abstract: Provided are compositions of cladribine and cyclodextrin which are especially suited for the oral and buccal administration of cladribine.

Abstract: The invention relates to the analytical determination of poloxamers in a liquid protein sample.

Abstract: A container comprising a closure means coated by an inert fluorinated material and containing a liquid pharmaceutical composition. In particular, the container comprises a closure means coated by TEFLON (polytetrafluoruethylene (PTFE)) and contains a HSA-free Interferon-? formulation having the following composition: 30 to 100 ?g/ml of interferon-?, an isotonicity agent, 0.1 to 2 mg/ml of Poloxamer 188, at least 0.12 mg/ml of L-Methionine and a buffer solution capable of maintaining the pH of the liquid formulation at a value between 3.0 and 4.0.